| Dr Kevin A Andryc, DO | |
|
201 State St, Erie, PA 16550-0002 | |
| (814) 877-6000 | |
| (814) 877-4010 |
| Full Name | Dr Kevin A Andryc |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 18 Years |
| Location | 201 State St, Erie, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013175835 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | OT011707 (Pennsylvania) | Secondary |
| 207P00000X | Emergency Medicine | 34-010094 (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Hospitals Geneva Medical Center | Geneva, OH | Hospital |
| University Hospitals Of Cleveland | Cleveland, OH | Hospital |
| Uh Conneaut Medical Center | Conneaut, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Emergency Specialists Llc | 4587807854 | 16 |
| Ues Geneva Llc | 4789827064 | 16 |
News Archive
Most people who attempt suicide make some type of healthcare visit in the weeks or months before the attempt, reports a study in the May issue of Medical Care, published by Wolters Kluwer.
Five researchers and leaders from The University of Texas MD Anderson Cancer Center have been named Fellows to a new academy launched by the world's oldest and largest organization dedicated to cancer research, the American Association for Cancer Research.
Allos Therapeutics, Inc. today announced that the Company has reached agreement with the U.S. Food and Drug Administration (FDA) under its Special Protocol Assessment (SPA) process for the design of the Company's Phase 3 clinical trial of FOLOTYN® (pralatrexate injection) in patients with previously undiagnosed peripheral T-cell lymphoma (PTCL).
Since insulin's crucial discovery nearly a century ago, countless diabetes patients have had to inject themselves with the life-saving medicine. Now scientists are reporting a new development toward a long-sought insulin pill that could save millions the pain of daily shots. Published in the ACS journal Biomacromolecules, the advance could someday not only eliminate the "ouch" factor, but also get needle-wary - and weary - patients to take their medicine when they should.
› Verified 8 days ago
| Entity Name | University Primary Care Practices Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003935339 PECOS PAC ID: 3072417534 Enrollment ID: O20031125000767 |
News Archive
Most people who attempt suicide make some type of healthcare visit in the weeks or months before the attempt, reports a study in the May issue of Medical Care, published by Wolters Kluwer.
Five researchers and leaders from The University of Texas MD Anderson Cancer Center have been named Fellows to a new academy launched by the world's oldest and largest organization dedicated to cancer research, the American Association for Cancer Research.
Allos Therapeutics, Inc. today announced that the Company has reached agreement with the U.S. Food and Drug Administration (FDA) under its Special Protocol Assessment (SPA) process for the design of the Company's Phase 3 clinical trial of FOLOTYN® (pralatrexate injection) in patients with previously undiagnosed peripheral T-cell lymphoma (PTCL).
Since insulin's crucial discovery nearly a century ago, countless diabetes patients have had to inject themselves with the life-saving medicine. Now scientists are reporting a new development toward a long-sought insulin pill that could save millions the pain of daily shots. Published in the ACS journal Biomacromolecules, the advance could someday not only eliminate the "ouch" factor, but also get needle-wary - and weary - patients to take their medicine when they should.
› Verified 8 days ago
| Entity Name | University Emergency Specialists Of Bedford Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760434781 PECOS PAC ID: 2466357801 Enrollment ID: O20031126000765 |
News Archive
Most people who attempt suicide make some type of healthcare visit in the weeks or months before the attempt, reports a study in the May issue of Medical Care, published by Wolters Kluwer.
Five researchers and leaders from The University of Texas MD Anderson Cancer Center have been named Fellows to a new academy launched by the world's oldest and largest organization dedicated to cancer research, the American Association for Cancer Research.
Allos Therapeutics, Inc. today announced that the Company has reached agreement with the U.S. Food and Drug Administration (FDA) under its Special Protocol Assessment (SPA) process for the design of the Company's Phase 3 clinical trial of FOLOTYN® (pralatrexate injection) in patients with previously undiagnosed peripheral T-cell lymphoma (PTCL).
Since insulin's crucial discovery nearly a century ago, countless diabetes patients have had to inject themselves with the life-saving medicine. Now scientists are reporting a new development toward a long-sought insulin pill that could save millions the pain of daily shots. Published in the ACS journal Biomacromolecules, the advance could someday not only eliminate the "ouch" factor, but also get needle-wary - and weary - patients to take their medicine when they should.
› Verified 8 days ago
| Entity Name | Physicians Link Center Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235172925 PECOS PAC ID: 8527969492 Enrollment ID: O20040405000838 |
News Archive
Most people who attempt suicide make some type of healthcare visit in the weeks or months before the attempt, reports a study in the May issue of Medical Care, published by Wolters Kluwer.
Five researchers and leaders from The University of Texas MD Anderson Cancer Center have been named Fellows to a new academy launched by the world's oldest and largest organization dedicated to cancer research, the American Association for Cancer Research.
Allos Therapeutics, Inc. today announced that the Company has reached agreement with the U.S. Food and Drug Administration (FDA) under its Special Protocol Assessment (SPA) process for the design of the Company's Phase 3 clinical trial of FOLOTYN® (pralatrexate injection) in patients with previously undiagnosed peripheral T-cell lymphoma (PTCL).
Since insulin's crucial discovery nearly a century ago, countless diabetes patients have had to inject themselves with the life-saving medicine. Now scientists are reporting a new development toward a long-sought insulin pill that could save millions the pain of daily shots. Published in the ACS journal Biomacromolecules, the advance could someday not only eliminate the "ouch" factor, but also get needle-wary - and weary - patients to take their medicine when they should.
› Verified 8 days ago
| Entity Name | Ues Richmond Heights Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568414613 PECOS PAC ID: 8224057047 Enrollment ID: O20051122000004 |
News Archive
Most people who attempt suicide make some type of healthcare visit in the weeks or months before the attempt, reports a study in the May issue of Medical Care, published by Wolters Kluwer.
Five researchers and leaders from The University of Texas MD Anderson Cancer Center have been named Fellows to a new academy launched by the world's oldest and largest organization dedicated to cancer research, the American Association for Cancer Research.
Allos Therapeutics, Inc. today announced that the Company has reached agreement with the U.S. Food and Drug Administration (FDA) under its Special Protocol Assessment (SPA) process for the design of the Company's Phase 3 clinical trial of FOLOTYN® (pralatrexate injection) in patients with previously undiagnosed peripheral T-cell lymphoma (PTCL).
Since insulin's crucial discovery nearly a century ago, countless diabetes patients have had to inject themselves with the life-saving medicine. Now scientists are reporting a new development toward a long-sought insulin pill that could save millions the pain of daily shots. Published in the ACS journal Biomacromolecules, the advance could someday not only eliminate the "ouch" factor, but also get needle-wary - and weary - patients to take their medicine when they should.
› Verified 8 days ago
| Entity Name | Ues Geauga, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841242997 PECOS PAC ID: 6406876002 Enrollment ID: O20051128000779 |
News Archive
Most people who attempt suicide make some type of healthcare visit in the weeks or months before the attempt, reports a study in the May issue of Medical Care, published by Wolters Kluwer.
Five researchers and leaders from The University of Texas MD Anderson Cancer Center have been named Fellows to a new academy launched by the world's oldest and largest organization dedicated to cancer research, the American Association for Cancer Research.
Allos Therapeutics, Inc. today announced that the Company has reached agreement with the U.S. Food and Drug Administration (FDA) under its Special Protocol Assessment (SPA) process for the design of the Company's Phase 3 clinical trial of FOLOTYN® (pralatrexate injection) in patients with previously undiagnosed peripheral T-cell lymphoma (PTCL).
Since insulin's crucial discovery nearly a century ago, countless diabetes patients have had to inject themselves with the life-saving medicine. Now scientists are reporting a new development toward a long-sought insulin pill that could save millions the pain of daily shots. Published in the ACS journal Biomacromolecules, the advance could someday not only eliminate the "ouch" factor, but also get needle-wary - and weary - patients to take their medicine when they should.
› Verified 8 days ago
| Entity Name | University Hospitals Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669499414 PECOS PAC ID: 4789682493 Enrollment ID: O20061113000301 |
News Archive
Most people who attempt suicide make some type of healthcare visit in the weeks or months before the attempt, reports a study in the May issue of Medical Care, published by Wolters Kluwer.
Five researchers and leaders from The University of Texas MD Anderson Cancer Center have been named Fellows to a new academy launched by the world's oldest and largest organization dedicated to cancer research, the American Association for Cancer Research.
Allos Therapeutics, Inc. today announced that the Company has reached agreement with the U.S. Food and Drug Administration (FDA) under its Special Protocol Assessment (SPA) process for the design of the Company's Phase 3 clinical trial of FOLOTYN® (pralatrexate injection) in patients with previously undiagnosed peripheral T-cell lymphoma (PTCL).
Since insulin's crucial discovery nearly a century ago, countless diabetes patients have had to inject themselves with the life-saving medicine. Now scientists are reporting a new development toward a long-sought insulin pill that could save millions the pain of daily shots. Published in the ACS journal Biomacromolecules, the advance could someday not only eliminate the "ouch" factor, but also get needle-wary - and weary - patients to take their medicine when they should.
› Verified 8 days ago
| Entity Name | University Emergency Specialists Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033454483 PECOS PAC ID: 4587807854 Enrollment ID: O20130905000711 |
News Archive
Most people who attempt suicide make some type of healthcare visit in the weeks or months before the attempt, reports a study in the May issue of Medical Care, published by Wolters Kluwer.
Five researchers and leaders from The University of Texas MD Anderson Cancer Center have been named Fellows to a new academy launched by the world's oldest and largest organization dedicated to cancer research, the American Association for Cancer Research.
Allos Therapeutics, Inc. today announced that the Company has reached agreement with the U.S. Food and Drug Administration (FDA) under its Special Protocol Assessment (SPA) process for the design of the Company's Phase 3 clinical trial of FOLOTYN® (pralatrexate injection) in patients with previously undiagnosed peripheral T-cell lymphoma (PTCL).
Since insulin's crucial discovery nearly a century ago, countless diabetes patients have had to inject themselves with the life-saving medicine. Now scientists are reporting a new development toward a long-sought insulin pill that could save millions the pain of daily shots. Published in the ACS journal Biomacromolecules, the advance could someday not only eliminate the "ouch" factor, but also get needle-wary - and weary - patients to take their medicine when they should.
› Verified 8 days ago
| Entity Name | Ues Geneva Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689919029 PECOS PAC ID: 4789827064 Enrollment ID: O20130905000813 |
News Archive
Most people who attempt suicide make some type of healthcare visit in the weeks or months before the attempt, reports a study in the May issue of Medical Care, published by Wolters Kluwer.
Five researchers and leaders from The University of Texas MD Anderson Cancer Center have been named Fellows to a new academy launched by the world's oldest and largest organization dedicated to cancer research, the American Association for Cancer Research.
Allos Therapeutics, Inc. today announced that the Company has reached agreement with the U.S. Food and Drug Administration (FDA) under its Special Protocol Assessment (SPA) process for the design of the Company's Phase 3 clinical trial of FOLOTYN® (pralatrexate injection) in patients with previously undiagnosed peripheral T-cell lymphoma (PTCL).
Since insulin's crucial discovery nearly a century ago, countless diabetes patients have had to inject themselves with the life-saving medicine. Now scientists are reporting a new development toward a long-sought insulin pill that could save millions the pain of daily shots. Published in the ACS journal Biomacromolecules, the advance could someday not only eliminate the "ouch" factor, but also get needle-wary - and weary - patients to take their medicine when they should.
› Verified 8 days ago
| Entity Name | Ues Ahuja Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467883934 PECOS PAC ID: 5496985467 Enrollment ID: O20140313001425 |
News Archive
Most people who attempt suicide make some type of healthcare visit in the weeks or months before the attempt, reports a study in the May issue of Medical Care, published by Wolters Kluwer.
Five researchers and leaders from The University of Texas MD Anderson Cancer Center have been named Fellows to a new academy launched by the world's oldest and largest organization dedicated to cancer research, the American Association for Cancer Research.
Allos Therapeutics, Inc. today announced that the Company has reached agreement with the U.S. Food and Drug Administration (FDA) under its Special Protocol Assessment (SPA) process for the design of the Company's Phase 3 clinical trial of FOLOTYN® (pralatrexate injection) in patients with previously undiagnosed peripheral T-cell lymphoma (PTCL).
Since insulin's crucial discovery nearly a century ago, countless diabetes patients have had to inject themselves with the life-saving medicine. Now scientists are reporting a new development toward a long-sought insulin pill that could save millions the pain of daily shots. Published in the ACS journal Biomacromolecules, the advance could someday not only eliminate the "ouch" factor, but also get needle-wary - and weary - patients to take their medicine when they should.
› Verified 8 days ago
| Entity Name | Magis Emergency Medicine, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801287511 PECOS PAC ID: 2769700392 Enrollment ID: O20150410002555 |
News Archive
Most people who attempt suicide make some type of healthcare visit in the weeks or months before the attempt, reports a study in the May issue of Medical Care, published by Wolters Kluwer.
Five researchers and leaders from The University of Texas MD Anderson Cancer Center have been named Fellows to a new academy launched by the world's oldest and largest organization dedicated to cancer research, the American Association for Cancer Research.
Allos Therapeutics, Inc. today announced that the Company has reached agreement with the U.S. Food and Drug Administration (FDA) under its Special Protocol Assessment (SPA) process for the design of the Company's Phase 3 clinical trial of FOLOTYN® (pralatrexate injection) in patients with previously undiagnosed peripheral T-cell lymphoma (PTCL).
Since insulin's crucial discovery nearly a century ago, countless diabetes patients have had to inject themselves with the life-saving medicine. Now scientists are reporting a new development toward a long-sought insulin pill that could save millions the pain of daily shots. Published in the ACS journal Biomacromolecules, the advance could someday not only eliminate the "ouch" factor, but also get needle-wary - and weary - patients to take their medicine when they should.
› Verified 8 days ago
| Entity Name | University Hospitals Conneaut Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831545177 PECOS PAC ID: 0547429656 Enrollment ID: O20161107001012 |
News Archive
Most people who attempt suicide make some type of healthcare visit in the weeks or months before the attempt, reports a study in the May issue of Medical Care, published by Wolters Kluwer.
Five researchers and leaders from The University of Texas MD Anderson Cancer Center have been named Fellows to a new academy launched by the world's oldest and largest organization dedicated to cancer research, the American Association for Cancer Research.
Allos Therapeutics, Inc. today announced that the Company has reached agreement with the U.S. Food and Drug Administration (FDA) under its Special Protocol Assessment (SPA) process for the design of the Company's Phase 3 clinical trial of FOLOTYN® (pralatrexate injection) in patients with previously undiagnosed peripheral T-cell lymphoma (PTCL).
Since insulin's crucial discovery nearly a century ago, countless diabetes patients have had to inject themselves with the life-saving medicine. Now scientists are reporting a new development toward a long-sought insulin pill that could save millions the pain of daily shots. Published in the ACS journal Biomacromolecules, the advance could someday not only eliminate the "ouch" factor, but also get needle-wary - and weary - patients to take their medicine when they should.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Kevin A Andryc, DO 9411 Ravenna Rd, Chardon, OH 44024-9161 Ph: () - | Dr Kevin A Andryc, DO 201 State St, Erie, PA 16550-0002 Ph: (814) 877-6000 |
News Archive
Most people who attempt suicide make some type of healthcare visit in the weeks or months before the attempt, reports a study in the May issue of Medical Care, published by Wolters Kluwer.
Five researchers and leaders from The University of Texas MD Anderson Cancer Center have been named Fellows to a new academy launched by the world's oldest and largest organization dedicated to cancer research, the American Association for Cancer Research.
Allos Therapeutics, Inc. today announced that the Company has reached agreement with the U.S. Food and Drug Administration (FDA) under its Special Protocol Assessment (SPA) process for the design of the Company's Phase 3 clinical trial of FOLOTYN® (pralatrexate injection) in patients with previously undiagnosed peripheral T-cell lymphoma (PTCL).
Since insulin's crucial discovery nearly a century ago, countless diabetes patients have had to inject themselves with the life-saving medicine. Now scientists are reporting a new development toward a long-sought insulin pill that could save millions the pain of daily shots. Published in the ACS journal Biomacromolecules, the advance could someday not only eliminate the "ouch" factor, but also get needle-wary - and weary - patients to take their medicine when they should.
› Verified 8 days ago
Jonathan Miller, Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 201 State St, Erie, PA 16550 Phone: 814-877-6139 | |
Susan E Robbins, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 7200 Peach St, Epn/hamot Urgent Care-upmc Unit 16, Erie, PA 16509 Phone: 814-860-3301 | |
Dr. Timothy Cheslock, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 232 W 25th St, Erie, PA 16544 Phone: 814-734-1618 Fax: 814-734-3102 | |
Caroline A Colleran, D.O. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 4950 Buffalo Rd, Erie, PA 16510 Phone: 814-898-2576 Fax: 570-644-4241 | |
Jacob Cauvel, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 201 State St, Erie, PA 16550 Phone: 814-877-6000 | |
Shawn M Simko, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 232 W 25th St, Erie, PA 16544 Phone: 814-452-5000 |